Tim Tyson leaves GSK for ICN
Tim Tyson, currently president, global manufacturing & supply, is leaving GlaxoSmithKline (GSK) to take up a new position as president and coo for ICN Pharmaceuticals, a research-based speciality pharmaceuticals company, based in Costa Mesa, California.
Tim Tyson, currently president, global manufacturing & supply, is leaving GlaxoSmithKline (GSK) to take up a new position as president and coo for ICN Pharmaceuticals, a research-based speciality pharmaceuticals company, based in Costa Mesa, California.
Dr David Pulman, currently senior vp - strategy, logistics & North American supply, global manufacturing & supply, GSK, will be named president, GMS, and will report to Robert Ingram, until Ingram's retirement on 31 December 2002.
Subsequently he will report to David Stout, who assumes the role of president, pharmaceuticals operations, from January 2003. Dr Pulman will be based in Research Triangle Park, North Carolina, US.
Jean-Pierre Garnier, ceo for GlaxoSmithKline said: 'Tim has done a great job in integrating two large global manufacturing networks and maintaining very high quality supply of our pharmaceutical products. I would like to thank him for his outstanding contribution to GSK. We are sorry to lose him and wish Tim the very best of luck in his new role.
'David is currently a member of GSK's global manufacturing & supply executive team, responsible for the north American supply network, manufacturing strategy and logistics. He brings a wealth of expertise to the role, having held many positions in the group's manufacturing operations, and we welcome him to GSK's corporate executive team and look forward to his contribution.'
Tyson said: 'I have been with GSK and its predecessors for more than 14 years, and very much enjoyed my time with the company, most recently in leading GSK's GMS operations, where I have worked with a terrific team of dedicated professionals. I now feel that the time is right to take on the role of running a company's global commercial operation. My new role at ICN Pharmaceuticals is a great opportunity for me in that respect.''